Cipla receives final approval for generic version of GlaxoSmit... - 02 March 2021 18:56

MUMBAI, India, 02 March 2021 /PRNewswire-AsiaNet/ -- Cipla Limited (BSE: 500087); (NSE: CIPLA EQ) (hereinafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Sumatriptan Nasal Spray, 20 mg from the United States Foo...

  Cipla Gulf Expands Partnership with Alvotech for Commercializa... - 02 March 2021 18:40

MUMBAI, India, March. 2, 2021/PRNewswire/ AsiaNet/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) referred to as "Cipla" today announced that its subsidiary, Cipla Gulf FZ LCC ("Cipla Gulf')is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines ...

  INOVIO Announces Positive Results from REVEAL 1, a Phase 3 Piv... - 02 March 2021 08:39

PLYMOUTH MEETING, Pa., March 2, 2021 /PRNewswire-AsiaNet/ -- -- Trial achieved primary and secondary efficacy endpoints among all evaluable subjects in the Phase 3 multi-center, randomized, double-blind, placebo-controlled trial -- VGX-3100 is the first DNA medicine to achieve efficacy endpoints in a Pha...

  Lennar Named #1 Homebuilder Worldwide on FORTUNE Magazine's 20... - 01 March 2021 21:00

MIAMI, March 1, 2021 /PRNewswire-AsiaNet/ -- Lennar Corporation (NYSE: LEN and LEN.B), the nation's leading homebuilder, today announced that it has been named #1 Most Admired Homebuilder on FORTUNE Magazine's 2021 List of World's Most Admired Companies ( https://c212.net/c/link/?t=0&l=en&o=...

  TVM Capital Healthcare Exits Cambridge Medical and Rehabilitat... - 01 March 2021 18:35

SINGAPORE, March 1, 2021 /PRNewswire-AsiaNet/ -- TVM Capital Healthcare, a global specialist healthcare private equity firm operating in emerging markets, announces the successful sale of its portfolio company Cambridge Medical and Rehabilitation Center ("CMRC") to UAE-based publicly traded ...

  Debiopharm And Genome & Company Join Forces To Create New High... - 26 February 2021 23:11

LAUSANNE, Switzerland and SEONGNAM-SI GYEONGGI-DO, South Korea, Feb. 26, 2021 /PRNewswire/ - Korean and Swiss based companies leverage their oncology expertise to initiate a research collaboration to formulate novel antibody-drug conjugate (ADC) candidates Genome & Company (CEO: Jisoo Pae, Hansoo Park), a global leading immuno-oncolo...

  New Data Presented at ACTRIMS Forum 2021 Indicate MAVENCLAD®-t... - 26 February 2021 00:25

DARMSTADT, Germany, Feb. 26, 2021 /PRNewswire-AsiaNet / -- MAGNIFY-MS retrospective analysis demonstrates patients develop protective antibody levels for at least six months following seasonal influenza and varicella zoster vaccines, irrespective of vaccine timing relative to MAVENCLAD dosing Initial f...

  Polyplastics Expands DURACON (R) POM PM Series with New High-f... - 25 February 2021 18:00

TOKYO, Feb. 25, 2021 /Kyodo JBN-AsiaNet/-- The Polyplastics Group is expanding its DURACON (R) polyoxymethylene (POM) PM series portfolio with the development of a new high-flow grade for drug contact and delivery applications for the medical and healthcare market. The new grade, DURACON P...

  New FDI World Dental Federation global survey reveals that two... - 25 February 2021 10:01

GENEVA, Feb. 24, 2021 /PRNewswire-AsiaNet/ -- -- Survey also shows that half of the responding countries have agreed to include dentists in their priority vaccination groups FDI World Dental Federation today [ http://www.fdiworlddental.org/vaccines ] called for more countries to enable...

  Occlutech announces Completion of Patient Enrolment in Pilot S... - 24 February 2021 23:58

SCHAFFHAUSEN, Switzerland, February 24, 2021, /PRNewswire-AsiaNet/-- Occlutech, a privately-held company, announced today the completion of patient enrolment in its pilot study to assess safety and efficacy of the novel Atrial Flow Regulator (AFR) in heart failure (HF) patients (PRELIEVE trial). PRELIEVE is a pr...